This study examined whether, and by what signaling and ionic mechanisms, pyrimidine nucleotides constrict rat cerebral arteries. Cannulated cerebral arteries stripped of endothelium and pressurized to 15 mmHg constricted in a dose-dependent manner to UTP. This constriction was partly dependent on the depolarization of smooth muscle cells and the activation of voltage-operated Ca 2ϩ channels. The depolarization and constriction induced by UTP were unaffected by bisindolylmaleimide I, a PKC inhibitor that abolished phorbol ester (PMA)-induced constriction in cerebral arteries. In contrast, the Rhokinase inhibitor Y-27632 attenuated the ability of UTP to both constrict and depolarize cerebral arteries. With patch-clamp electrophysiology, a voltage-dependent delayed rectifying K ϩ (KDR) current was isolated and shown to consist of a slowly inactivating 4-aminopyridine (4-AP)-sensitive and an -insensitive component. The 4-APsensitive K DR current was potently suppressed by UTP through a mechanism that was not dependent on PKC. This reflects observations that demonstrated that 1) a PKC activator (PMA) had no effect on KDR and 2) PKC inhibitors (calphostin C or bisindolylmaleimide I) could not prevent the suppression of KDR by UTP. The Rho kinase inhibitor Y-27632 abolished the ability of UTP to inhibit the K DR current, as did inhibition of RhoA with C3 exoenzyme. Cumulatively, these observations indicate that Rho kinase signaling plays an important role in eliciting the cerebral constriction induced by pyrimidine nucleotides. Moreover, they demonstrate for the first time that Rhokinase partly mediates this constriction by altering ion channels that control membrane potential and Ca 2ϩ influx through voltage-operated Ca 2ϩ channels.
vasoconstrictors; membrane potential; potassium channels; protein kinase C AN INTEGRATED NETWORK of resistance arteries controls the magnitude and distribution of blood flow within cerebral tissue. Under dynamic conditions, tone within the cerebral network is regulated by multiple stimuli produced by changes in tissue metabolism (14) , neural activity (38) , blood flow (11) , and intravascular pressure (15, 21) . Many vasoactive stimuli initiate changes in arterial tone by activating transduction pathways associated with G protein-coupled receptors. It is key proteins within such pathways that in turn influence the Ca 2ϩ sensitivity of the myofilament (39) and/or ion channels that control cytosolic Ca 2ϩ through changes in resting membrane potential (28) .
Pyrimidine nucleotides such as UTP and UDP are released from cells that are part of, or pass through the lumen of, resistance arteries (23, 31) . These sources include activated platelets and endothelial cells (25, 36) . In the cerebral circulation, the binding of pyrimidine nucleotides to P2Y receptors can both dilate and constrict resistance arteries, depending on which population of receptors is recruited (17, 27) . Endothelial P2Y receptors mediate cerebral artery dilation through the enhanced production of endothelium-derived factors including nitric oxide (26, 27, 31) . In contrast, it is P2Y receptors on smooth muscle that are responsible for cerebral artery constriction (17, 27) .
The mechanisms that enable smooth muscle P2Y receptors to constrict the cerebral vasculature have been poorly defined. Jaggar and Nelson (18) , in one of the few investigations to address the issue, theorized a prominent role for electromechanical coupling in the overall transduction process. In greater detail, these investigators argued that the activation of pyrimidine-sensitive P2Y receptors enhances PKC activity via G q , phospholipase C␤, and the production of diacylglycerol. By altering the phosphorylation state of key proteins, this serine/ threonine kinase was subsequently proposed to inhibit outward K ϩ conductance and thereby initiate depolarization (18) . In cerebral smooth muscle, K ϩ conductance is determined by four families of K ϩ channels including those that underlie the inwardly rectifying, the ATP-sensitive, the large-conductance Ca 2ϩ -activated (BK), and the voltage-dependent delayed rectifying (K DR ) K ϩ currents (28) . With the exception of the inwardly rectifying K ϩ channels, all of these K ϩ conductances display sensitivity to PKC and thus, in theory, could be targeted and suppressed by pyrimidine nucleotides (1, 4, 5) .
This study examined whether, and by what signaling and ionic mechanisms, pyrimidine nucleotides constrict rat cerebral arteries. We report that UTP-induced constriction partly depends on the depolarization of cerebral smooth muscle cells and the activation of voltage-operated Ca 2ϩ channels. Contrary to initial expectations, the depolarization and constriction induced by UTP did not depend on PKC but rather arose from the activation of Rho kinase. Such findings indicate that, in addition to regulating myosin light chain phosphatase, Rho kinase likely targets other downstream effectors of smooth muscle cell contraction including ion channels. Electrophysiological measurements indicate that the slowly inactivating 4-aminopyridine (4-AP)-sensitive K DR current is one of the ionic conductances suppressed by UTP through a signaling pathway that involves RhoA/Rho kinase and not PKC. In summary, our findings are the first to establish RhoA/Rho kinase as a mod-ulator of ion channels that control smooth muscle membrane potential (E m ). K DR current suppression by RhoA/Rho kinase likely plays an important role in enabling pyrimidine-sensitive P2Y receptors to depolarize and consequently constrict intact cerebral arteries.
MATERIALS AND METHODS
Animal procedures and tissue preparation. All procedures were approved by the University of Calgary Animal Care and Use Committee. Briefly, female Sprague-Dawley rats (10-12 wk of age) were euthanized by carbon dioxide asphyxiation. The brain was carefully removed and placed in cold phosphate-buffered saline containing (in mM) 138 NaCl, 3 KCl, 10 Na2HPO4, 2 NaH2PO4, 5 glucose, 0.1 CaCl2, and 0.1 MgSO4 (pH 7.4). Cerebellar and cerebral arteries were dissected free of the surrounding tissue and cut into 2-mm segments.
Intact cerebral arteries. Cerebral arteries were mounted in a customized arteriograph chamber (J. B. Pierce Laboratory, New Haven, CT) and superfused with warm (37°C) physiological salt solution containing (in mM) 119 NaCl, 4.7 KCl, 20 NaHCO3, 1.7 KH2PO4, 1.2 MgSO4, 1.6 CaCl2, and 10 glucose (pH 7.4). Endothelial cells were removed from all arteries by passing air bubbles through the vessel lumen for 2 min; successful removal was confirmed by the loss of acetylcholine-induced dilations. In keeping with past studies (43, 44) , cannulated arteries were pressurized to 15 mmHg. Low intravascular pressure minimizes myogenic tone and enables investigators to study the effects of pyrimidine nucleotides with and without inhibitors in isolation. Arterial diameter was monitored with an automated edge detection system (IonOptix, Milton, MA). Smooth muscle E m was assessed by inserting a glass microelectrode filled with 1 M KCl (tip resistance ϭ 120-150 M⍀) carefully into the vessel wall. The criteria for successful cell impalement were 1) a sharp negative E m deflection on entry, 2) a stable recording for at least 1 min after entry, and 3) a sharp return to baseline on electrode removal. Because E m recordings were typically limited to 3-10 min, a distinct impalement was required to measure E m under each experimental condition.
Experimental protocol and intact cerebral arteries. Cerebral arteries were equilibrated for 60 min at 37°C. Before experimentation, the vessel's contractile state was determined by briefly (ϳ10 s) exposing the tissue to a 6 ϫ 10 Ϫ2 M KCl challenge. Dose responsiveness of cerebral arteries to UTP, UDP, and U-46619 was ascertained by increasing agonist concentration every 10 min and monitoring arterial diameter. To study the effects of PKC, Rho kinase, and voltageoperated Ca 2ϩ channel inhibition, cerebral arteries were preconstricted with agonist and then exposed to bisindolylmaleimide I (10 Ϫ8 -3 ϫ 10 Ϫ6 M), Y-27632 (10 Ϫ7 -3 ϫ 10 Ϫ5 M), and diltiazem (3 ϫ 10 Ϫ5 M), respectively. It should be noted that agonist concentration was varied slightly among experiments (UTP, 10 Ϫ6 -10 Ϫ5 M; U-46619, 10 Ϫ9 -10 Ϫ8 M) to set the initial constrictor response at 70-90% of maximum.
Preparation of isolated arterial smooth muscle cells. Smooth muscle cells from rat cerebral arteries were enzymatically isolated as previously described (44) . In brief, arterial segments were placed in warm (37°C) cell isolation medium containing (in mM) 60 NaCl, 80 Na-glutamate, 5 KCl, 2 MgCl 2, 10 glucose, and 10 HEPES with 1 mg/ml albumin (pH 7.2) for 10 min. After this equilibration step, arterial segments were initially incubated (37°C) in 0.6 mg/ml papain and 1.8 mg/ml dithioerythritol for 15 min. This was followed by a second incubation (37°C) in isolation medium containing 100 M Ca 2ϩ , 0.7 mg/ml type F collagenase, and 0.4 mg/ml type H collagenase for 10 min. After enzyme treatment, the tissue was washed three times in ice-cold isolation medium and triturated with a fire-polished pipette to release the myocytes. Cells were stored in ice-cold isolation medium for use the same day. 
, or C3 exoenzyme (10 g/ml ϩ 5 ϫ 10 Ϫ5 M NAD ϩ ) before the addition of UTP. Bisindolylmaleimide I, calphostin C, and Y-27632 were continuously superfused in the bath, whereas C3 exoenzyme-NAD ϩ was added to the pipette solution. In general, the net current-voltage relationship was determined at 5-min intervals by measuring the peak current at the end of a 300-ms pulse to voltages between Ϫ70 and ϩ40 mV. After each 300-ms pulse, cells were voltage clamped to Ϫ40 mV (500 ms) to facilitate the monitoring of tail currents. Tail current amplitude was used to assess steady-state activation and was calculated as the difference between the peak amplitude of the tail and the sustained level of current at Ϫ40 mV. Steady-state inactivation was ascertained by measuring peak outward current at ϩ20 mV (200-ms voltage step) after a series of prolonged test pulses (45 s) ranging from Ϫ90 to 0 mV. Data were fitted to a Boltzmann distribution function so that the voltages for half-maximal activation and inactivation could be calculated.
RT-PCR analysis and isolated smooth muscle cells. Approximately 300 smooth muscle cells were enzymatically isolated from cerebral and cerebellar arteries and placed in RNase-and DNasefree collection tubes. After total RNA extraction (RNeasy mini kit with DNase treatment; Qiagen, Valencia, CA), first-strand cDNA was synthesized with the Sensiscript RT kit (Qiagen). Subsequently, 2 l of each first-strand cDNA reaction were used as the template in a PCR reaction containing 1.5 mM MgCl2, 0.25 M forward and reverse primers (University of Calgary), 0.2 mM deoxynucleotide triphosphates; and 2.5 units of recombinant Taq DNA polymerase. PCR reactions were hot started (94°C for 3 min) and underwent 35 cycles of 94°C for 1.0 min, 60°C for 0.5 min, and 72°C for 0.75 min. PCR samples were then exposed to a final extension period at 72°C for 10 min. Forward and reverse primers specific to rat P2Y2, P2Y4, and P2Y6 were as follows: P2Y2 (forward) 5Ј-TTCCACGTCACCCGCACCCTCTTATTACT-3Ј, P2Y2 (reverse) 5Ј-CGATTCCCCAACTCACACATACAAATGATTG-3Ј; P2Y4 (forward) 5Ј-CTTCTCTGCCTGGGTGTTTGGTTGGTAGTA-3Ј, P2Y4 (reverse) 5Ј-TCCCCCGTGAAGAGATAGAGCACTGGA-3Ј; and P2Y6 (forward) 5Ј-GCCAGTTATGGAGCGGGACAATGG-3Ј, P2Y6 (reverse) 5Ј-AGGAACAGGATGCTGCCGTGTAGGTTG-3Ј.
The expected amplicon sizes for P2Y2, P2Y4, and P2Y6 were 539, 473, and 357 bp, respectively. DNA sequencing was used to identify each reaction product. Control experiments confirmed the absence of genomic DNA contamination by assessing where an Rho kinase-specific amplicon could be generated from samples exposed to RNase.
Chemicals, drugs and enzymes. Buffer reagents, UTP, NAD ϩ , collagenase (types F and H), and diltiazem were obtained from Sigma (St. Louis, MO). PMA, bisindolylmaleimide I, Y-27632, C3 exoenzyme, and U-46619 were purchased from Calbiochem (La Jolla, CA). PMA, bisindolylmaleimide I, and C3 exoenzyme were dissolved in DMSO, with the final solvent concentration Յ0.05%.
Statistical analysis. Data are expressed as means Ϯ SE, and n indicates the number of vessels or cells. The EC 50 of a given agonist was ascertained by fitting a four-parameter logistic function to the observed data. Paired t-tests were performed to statistically compare the effects of a given condition or treatment on arterial diameter, E m, or whole cell current. If more than two conditions or treatments were being compared, a repeated-measures ANOVA was used. When appropriate, a Tukey-Kramer pairwise comparison was used for post hoc analysis. P values Յ0.05 were considered statistically significant.
RESULTS

Vasomotor and E m measurements of intact cerebral arteries.
The addition of pyrimidine nucleotides to the superfusate elicited dose-dependent constrictions in cerebral arteries pressurized to 15 mmHg (to minimize myogenic tone) and stripped of endothelium (UTP, EC 50 ϭ 3.1 ϫ 10 Ϫ6 M; UDP, EC 50 ϭ 3.2 ϫ 10 Ϫ6 M; Fig. 1 , A and B). The sustained nature of this constriction is indicative of P2Y receptor activation and contrasts sharply with the transient constrictions elicited by agonists known to modulate P2X receptors (2) . RT-PCR analysis performed on ϳ300 cerebral smooth muscle cells revealed product bands with the predicted sizes of 539, 473, and 357 bp for P2Y2, P2Y4, and P2Y6 receptors, respectively (Fig. 1C) . DNA sequencing confirmed the identity of all PCR products.
Cerebral smooth muscle cells depolarized from Ϫ56.8 Ϯ 0.8 to Ϫ37.1 Ϯ 1.6 mV in the presence of UTP (Fig. 2, A and B) . Diltiazem (3 ϫ 10 Ϫ5 M), an inhibitor of voltage-operated Ca 2ϩ channels, attenuated UTP-induced constriction by 31.3 Ϯ 4.8%, indicating that tone development partly depended on depolarization (Fig. 2, C and D) ; nifedipine (1 ϫ 10 Ϫ6 M; n ϭ 2) was also noted to attenuate constriction (data not shown). Given that P2Y receptors can activate PKC (18) , subsequent experiments examined whether this kinase enabled UTP to both constrict and depolarize the cerebral vasculature. The PKC activator PMA (3 ϫ 10 Ϫ8 M) initiated a sustained constriction that was abolished by preincubation with bisindolylmaleimide I (10 Ϫ7 M; Fig. 3A ). Despite its effectiveness as a PKC inhibitor, UTP-constricted arteries did not dilate to the application of bisindolylmaleimide I at concentrations ranging from 10 Ϫ8 to 3 ϫ 10 Ϫ7 M (Fig. 3, B and C) . Preincubation of vessels with bisindolylmaleimide I (1 ϫ 10 Ϫ7 M) before the addition of UTP (5 M) was also ineffective at attenuating constriction [diameter response in m (n ϭ 5): control, 77.1 Ϯ 5.7; bisindolylmaleimide I, 74.3 Ϯ 7.1]. Bisindolylmaleimide I did not prevent UTP from depolarizing cerebral smooth muscle cells (Fig. 3, C and D) .
Contrary to the preceding observations, the Rho kinase inhibitor Y-27632 dilated cerebral arteries preconstricted with UTP (Fig. 4, A and B) . This attenuating effect was dose dependent, with 74.0 Ϯ 5.9% (n ϭ 7) of the agonist-induced constriction eliminated at a Y-27632 concentration of 3 ϫ
10
Ϫ5 M. In addition to its effects on agonist-induced tone, Y-27632 attenuated the ability of UTP to depolarize cerebral smooth muscle cells by 13.8 Ϯ 2.1 mV (Fig. 4, C and D) . The effects of Y-27632 on arterial diameter and E m cannot be ascribed to alterations in myogenic signaling because vessels were maintained at low intravascular pressure (15 mmHg).
Patch-clamp electrophysiology and isolated smooth muscle cells. With conventional whole cell patch-clamp electrophysiology and pipette solutions that minimize BK channel activity, the K DR current was isolated in rat cerebral smooth muscle cells. In general, brief voltage steps positive to Ϫ30 mV activated K DR without an induction of inactivation (Fig. 5A) . Steady-state activation and inactivation were ascertained by monitoring 1) tail currents (at Ϫ40 mV) after a set of 300-ms voltage pulses (range Ϫ70 to ϩ40 mV) and 2) peak outward current (at ϩ20 mV) after a series of prolonged test potentials (45 s, range Ϫ90 to Ϫ10 mV; Fig. 5B ). Data fitted to a Boltzmann function established voltages for half-maximal activation and inactivation of ϩ1.5 and Ϫ36.2 mV, respectively (Fig. 5C) . At ϩ40 mV, the K DR current was stable over time: a small but significant current run-up was noted at Ϫ20 mV (P Յ 0.05; Fig. 5D ).
K DR currents in cerebral smooth muscle cells are comprised of two slowly inactivating components that vary in their sensitivity to 4-AP (33). In accordance with past studies (1, 33), 4-AP (5 ϫ 10 Ϫ3 M) partially suppressed the K DR current, thereby revealing both the 4-AP-sensitive and -insensitive components (Fig. 6, A and B) . The slowly inactivating 4-APsensitive component of the K DR current represented 37.9 Ϯ 3.8% of the total whole cell current at ϩ40 mV. Superfused iberiotoxin had no significant effect on peak outward current, confirming that high pipette concentrations of EGTA minimize the activity of BK channels (Fig. 6C) .
UTP modulation of K DR current. As shown in Figs. 1 and 2 , pyrimidine nucleotides depolarize and constrict cerebral arteries. Consistent with the view that this depolarization partly depends on the modulation of outward K ϩ conductance, UTP (3 ϫ 10 Ϫ5 M) was observed to inhibit K DR by 35.0 Ϯ 3.4% at ϩ40 mV (Fig. 7, A and B) . Characteristically, K DR current suppression was observable 5-10 min after the addition of UTP, with peak inhibition occurring at 20 min. In the presence of 4-AP (5 ϫ 10 Ϫ3 M), UTP had no effect on the remaining whole cell K DR current (Fig. 7C) . Such observations are consistent with pyrimidine nucleotides modulating the 4-APsensitive component of the K DR current.
Subsequent experiments defined whether PKC enables UTP to suppress the 4-AP-sensitive component of the K DR current. PMA initiated a sustained constriction in intact cerebral arteries that was abolished by the PKC inhibitors calphostin C and bisindolylmaleimide I [diameter response in m: PMA (3 ϫ 10 Ϫ8 M), 75.7 Ϯ 8.8; calphostin C (2 ϫ 10 Ϫ7 M) ϩ PMA, 1.2 Ϯ 1.5; see Fig. 2A for bisindolylmaleimide I] . Despite the effectiveness of PMA as a PKC activator, this agent (5 ϫ 10 Ϫ8 M) had no discernible effect on the K DR current (Fig. 8) . The ability of UTP to suppress the K DR current was not blocked by preincubating cerebral smooth muscle cells with calphostin C (2 ϫ 10 Ϫ7 M; Fig. 9 , A and C) or bisindolylmaleimide I (1 ϫ 10 Ϫ7 M; Fig. 9 , B and C).
In light of recent observations showing that the UTP-sensitive P2Y receptor can activate RhoA and Rho kinase (37) , subsequent experiments examined whether these signaling proteins enable UTP to suppress the 4-AP-sensitive component of the K DR current. Under resting conditions, the application of Y-27632 (3 ϫ 10 Ϫ5 M) elicited a small but statistically insignificant increase in whole cell K DR current (Fig. 10) . Although the effects of Y-27632 were small under basal conditions, this Rho kinase inhibitor abolished the ability of UTP to suppress K DR . Inhibiting RhoA activation with C3 exoenzyme (10 g/ml) also eliminated the UTP-induced suppression of K DR (Fig. 11, A and C) . Control experiments confirmed that NAD ϩ alone could not prevent UTP from suppressing the K DR current (Fig. 11, B and D) .
U-46619 and intact cerebral arteries. Further experiments tested whether the thromboxane mimetic U-46619 constricts and depolarizes cerebral arteries through a transduction process that also involves Rho kinase rather than PKC. As shown in Fig. 12A , U-46619 elicited a dose-dependent constriction in cerebral arteries stripped of endothelium and pressurized to 15 mmHg to minimize myogenic tone (EC 50 ϭ 1.7 ϫ 10 Ϫ9 M). This constriction was not blocked by bisindolylmaleimide I [diameter in m (n ϭ 6): control, 226.5 Ϯ 8.3; U-46619, 137.2 Ϯ 7.4; U-46619 ϩ bisindolylmaleimide I, 133.3 Ϯ 8.2] but was attenuated in a dose-dependent manner by Y-27632 (Fig. 12, B and C) . U-46619 initiated a depolarization in cerebral smooth muscle cells that was unaffected by bisindolylmaleimide I (Fig. 12D) . In contrast, when bisindolylmaleimide I and Y-27632 were applied together, the depolarization induced by U-46619 was diminished by 9.4 Ϯ 0.6 mV.
DISCUSSION
We present evidence here that UTP constricts rat cerebral arteries through a mechanism that partly depends on smooth muscle cell depolarization and the activation of voltage-operated Ca 2ϩ channels. Surprisingly, the depolarization and constriction induced by UTP was independent of PKC and instead arose from the activation of Rho kinase. Such findings indicate that Rho kinase likely targets ion channels involved in E m regulation. Electrophysiological measurements demonstrate that one of the ionic conductances regulated by UTP via Rho kinase is the slowly inactivating 4-AP-sensitive K DR current. In summary, it is Rho kinase signaling that enables UTP to control both the electrical and the contractile state of cerebral smooth muscle cells.
Pyrimidine nucleotides and cerebral vasculature. Pyrimidine nucleotides such as UTP and UDP are important signaling compounds released from cells during mechanical stress and cellular injury (23) . When secreted in close proximity to cerebral smooth muscle cells, these agents elicit a sustained constrictor response (12, 19, 27) . This maintained constriction was readily observed in the present study and is the result of P2Y receptor activation. Molecular studies have identified at least five subtypes of P2Y receptors that are coupled to trimeric G proteins (3, 31) . Pyrimidine nucleotides potently activate three of these subtypes (i.e., P2Y2, P2Y4, and P2Y6), all of which are expressed at the mRNA level in isolated cerebral smooth muscle cells. To elicit constriction, pyrimidine-sensitive P2Y receptors must activate a signaling pathway that enhances the Ca 2ϩ sensitivity of the myofilament (39) or increases cytosolic Ca 2ϩ through mechanisms that are either dependent or independent of resting membrane potential (28) . Two key findings support the view that electromechanical coupling plays an important role in enabling UTP to constrict cerebral arteries. First, the bath application of UTP depolarized cerebral smooth muscle cells by 19.6 Ϯ 1.6 mV. Second, inhibiting depolarization-induced increases in Ca 2ϩ channel activity (with diltiazem) attenuated constriction by Ͼ30%. At present, there is little consensus as to which signaling mechanisms enable pyrimidine-sensitive P2Y receptors to depolarize and constrict intact cerebral arteries. Of the few studies conducted in this area, Jaggar and Nelson (18) proposed a prominent role for PKC, a serine/threonine kinase coupled to P2Y receptors through G q , phospholipase C␤, and the production of diacylglycerol. This hypothesis was predicated on patch-clamp observations of spontaneous transient outward currents but did not involve a direct examination of intact cerebral arteries (18) . Surprisingly, when this study applied a confirmed PKC inhibitor to cerebral arteries preconstricted with UTP, there was no measurable effect on either constriction or depolarization.
Although PKC activation is not a key factor in enabling UTP-sensitive P2Y receptors to depolarize or constrict cerebral arteries, these findings should not be interpreted to suggest that arterial constriction is independent of G q signaling. Indeed, pyrimidine nucleotides have been observed in cerebral arteries to induce Ca 2ϩ waves, transitory Ca 2ϩ events driven by phospholipase C␤ activation and the production of inositol (1,4,5)-trisphosphate (18) . Although Ca 2ϩ waves have been associated with arterial constriction (10, 35) , studies have yet to resolve how a periodic event can elicit sustained constriction. We propose that a sustained constrictor response could be achieved if Ca 2ϩ wave activation coincided with an inhibition of myosin light chain phosphatase. Indeed, it could be the combination of Ca 2ϩ waves and phosphatase inhibition (via Rho kinase) that underlies a significant part of the UTP-mediated constriction insensitive to Ca 2ϩ channel blockade. The periodic release of Ca 2ϩ may also stimulate store-operated channels that in theory could increase cytosolic Ca 2ϩ and elicit a constriction independent of membrane potential.
Recent findings in the coronary circulation have shown that pyrimidine-induced contraction can be effectively abolished by the Rho kinase inhibitor Y-27632 (37) . From these observations, it was hypothesized that UTP-sensitive P2Y receptors mediate arterial constriction by activating G 12/13 and its associated signaling pathway including p115 Rho guanine nucleotide exchange factor (GEF), RhoA, and Rho kinase (37) . Observations from the current study indicate that Rho kinase signaling is also important in the regulation of cerebral vascular tone. More specifically, we observed that cerebral arteries preconstricted with UTP dilated in a dose-dependent manner to Y-27632. The vascular literature characteristically assumes that if Rho kinase inhibition impairs arterial constriction, such an alteration must exclusively reflect a change in the Ca 2ϩ sensitivity of the myofilament (37, 40) . This assumption arises from the known ability of Rho kinase to target and regulate myosin light chain phosphatase (40, 42) . Although an important regulator of pharmacomechanical coupling, Rho kinase could conceivably target other downstream effectors of smooth muscle cell contraction including ion channels involved in membrane potential regulation. Consistent with this view, Y-27632 was observed to reverse the depolarization initiated by UTP. These physiological findings appear to be the first in the resistance vasculature to support a role for Rho kinase in the regulation of ion channel activity and electromechanical coupling.
To depolarize cerebral smooth muscle cells, P2Y receptors along with Rho kinase must enhance depolarizing inward currents and/or inhibit hyperpolarizing K ϩ conductances. Although voltage-operated Ca 2ϩ (34) , nonselective cation (44), and four distinct K ϩ (28) currents have been isolated in cerebral smooth muscle cells, studies have never ascertained whether any of these conductances are sensitive to Rho kinase modulation. Despite this lack of evidence in native tissue, findings in expression systems have shown that voltage-dependent K DR channels may be one of the primary targets (6). This view is based on the work of Cachero et al. (6) , who observed the ability of G protein-coupled receptors to suppress Kv1.2 by activating RhoA, the upstream regulator of Rho kinase. Intriguingly, Kv1.2 is one of the key pore-forming subunits of the slowly inactivating 4-AP-sensitive K DR channel in vascular smooth muscle (20, 43) . This K DR channel contributes to resting E m , and its inhibition by vasoconstrictors is known to induce arterial depolarization (7, 16) . In light of these observations, a supplemental examination was undertaken to examine the relationship between pyrimidine nucleotides and K DR channel regulation.
K DR current in cerebral smooth muscle cells. Conventional whole cell patch-clamp electrophysiology was used to isolate and examine the K DR current in cerebral smooth muscle cells. Generally speaking, whole cell K DR current was characterized by 1) measurable activation at voltages positive to Ϫ30 mV, 2) slow time-dependent inactivation, and 3) voltages of halfmaximal activation and inactivation of ϩ1.5 and Ϫ36.1 mV, respectively. These documented K DR properties are similar to those in rat mesenteric arteries (16) and indicate that steadystate K DR current will be small at physiological E m (Ϫ30 to Ϫ60 mV). Despite their limited magnitude, the high input resistance of vascular smooth muscle cells (5-20 G⍀) dictates that such currents will play an important role in controlling membrane potential (28) . Like K DR , outward current through inwardly rectifying K ϩ channels and inward current through nonselective cation channels are equally small and difficult to monitor with patch-clamp electrophysiology (30, 32, 44) . Nevertheless, both currents have been shown to alter the resting E m of intact cerebral arteries by 10-15 mV (22, 44) . Quantitative three-dimensional electrical models of the resistance vasculature also indicate that small currents are functionally relevant and important to dynamic vessel function (45) .
The K DR current in vascular smooth muscle is divisible into distinct components that include 1) a slowly inactivating 4-APsensitive current, 2) a slowly inactivating 4-AP-insensitive current, and 3) a rapidly inactivating 4-AP-sensitive A-type current (K TO ; Refs. 1 and 20). Unlike portal vein, K TO current could not be discerned in cerebral smooth muscle cells. The slowly inactivating currents were, however, readily observable, with the 4-AP-sensitive component representing 37.9 Ϯ 3.7% of the overall current. Interestingly, this proportion is sizably smaller than that previously reported for portal vein (7) and pulmonary (8) arteries. Although work is limited in the resistance vasculature, observations in portal vein have implicated Kv1.2 and Kv1.5 as the key pore-forming subunits of 4-APsensitive channels (20) . In contrast, the pore-forming subunits of 4-AP-insensitive channels are thought to include members of the Kv7 family (29) .
UTP-induced regulation of K DR current. Intact vessel measurements demonstrated that pyrimidine nucleotides constrict intact cerebral arteries through a mechanism that partly depends on smooth muscle cell depolarization and Ca 2ϩ influx through voltage-operated Ca 2ϩ channels (18) . Consistent with depolarization arising from a reduction in outward K ϩ conductance, UTP was observed to potently suppress the K DR current. This suppression of K DR was particularly evident at positive potentials where the current is large and less susceptible to subtle time-dependent changes in current amplitude and seal resistance. The onset of current suppression typically began 5-10 min after agonist application and peaked by 20 min. The slow nature of agonist-induced current suppression was not entirely unexpected in light of past findings (7) and given that the current experiments were performed on enzymatically isolated cells maintained at room temperature and under conditions that result in significant cellular dialysis. The two slowly inactivating components of K DR current were differentially affected by this pyrimidine nucleotide. More specifically, UTP elicited a near-complete inhibition of the 4-AP-sensitive current whereas the 4-AP-insensitive component remained unaffected. Although this study is the first to demonstrate that pyrimidine-sensitive P2Y receptors target specific K DR channels, this pattern of preferential regulation is not unique. For example, vasoconstrictors such as angiotensin II have been reported to selectively suppress 4-AP-sensitive K DR currents in portal vein (7) . Correspondingly, activators of PKA and PKC have been shown to preferentially target the same K DR channels (1, 9) . Such observations support the view that 4-APsensitive channels are more tightly controlled by phosphorylation events than K DR channels insensitive to this K ϩ channel blocker (7) .
To inhibit the slowly inactivating 4-AP-sensitive component of the K DR current, UTP-sensitive P2Y receptors must activate a trimeric G protein along with its associated signaling cascade. Traditionally, it has been asserted that this receptor class is coupled to G q and its downstream effectors including phospholipase C␤ and PKC (24, 41) . PKC is a serine/threonine kinase whose activity is known to suppress 4-AP-sensitive K DR channels in portal vein and mesenteric artery (1, 7, 16) . Although UTP-sensitive P2Y receptors can in theory stimulate PKC, two key findings indicate that this kinase is not responsible for K DR current suppression in cerebral artery myocytes. First, the PKC activator PMA failed to inhibit K DR when applied at concentrations known to constrict intact cerebral arteries. Second, preincubation of cerebral smooth muscle cells with PKC inhibitors (calphostin C or bisindolylmaleimide I) did not prevent UTP from suppressing the K DR current. These electrophysiological findings nicely parallel functional observations that demonstrated that PKC inhibition did not impair the depolarization of intact cerebral arteries by UTP. Although Rho kinase is conventionally viewed as a regulator of Ca 2ϩ sensitivity, it is conceivable for this phosphotransferase protein along with its upstream regulator RhoA to mediate K DR current suppression by UTP (6) . Supporting a role for Rho kinase signaling, Y-27632 was observed in this study to prevent UTP from inhibiting K DR in isolated cerebral myocytes. Likewise, the RhoA inhibitor C3 exoenzyme was also effective at preventing pyrimidine nucleotides from regulating K DR . Physiological implications. In summary, this study demonstrated that pyrimidine nucleotides constrict intact cerebral arteries through a mechanism that partly involves the depolarization of vascular smooth muscle cells and the activation of voltage-operated Ca 2ϩ channels. We report for the first time in cerebral arterial smooth muscle that depolarization is dependent on the activation of Rho kinase and not PKC. One of the ionic conductances inhibited by UTP via Rho kinase is the 4-AP-sensitive K DR current. We hypothesize that pyrimidinesensitive P2Y receptors activate Rho kinase through a signal transduction cascade that involves G 12/13 , p115 Rho GEF, and RhoA (Fig. 13) . It is conceivable that Rho kinase regulation of ion channels might be narrowly limited to the cerebral vasculature or to the preceding receptor class. This view, however, is challenged by recent mesenteric observations showing that Rho kinase inhibition partially attenuates norepinephrine-induced depolarization (13) as well as by the findings shown in Fig. 12 , which indicate that the thromboxane mimetic U-46619 also depolarizes and constricts cerebral arteries by activating Rho kinase and not PKC. Further investigation is required to determine whether other ion channels are modulated by Rho kinase and thus contribute to the depolarizations induced by UTP and other constrictor agonists. Indeed, the recent observations by Ghisdal et al. (13) have indirectly implied that this serine/threonine kinase could activate a depolarizing nonselective cation current. In closing, we suggest that in the cerebral circulation Rho kinase regulation may be a common mechanism by which G protein-coupled receptors control both the electrical and the contractile state of vascular smooth muscle.
